Company research
UNITED THERAPEUTICS Corp
CIK 1082554Updated Sep 24, 2026
SecurityUTHR · NASDAQ · equity
UTHR price & chart
Loading TradingView…
NASDAQ:UTHR on TradingView ↗About the company
Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build.
In the news
No coverage from other publishers is available.
Recent filings
144 filing
4 filing
4 filing
144 filing
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 7,880,000,000Source | 7,364,000,000Source | 7,167,000,000Source | 6,044,500,000Source |
| Property, Plant and Equipment, NetUSD | 1,729,700,000Source | 1,222,400,000Source | 1,045,400,000Source | 861,500,000Source |
| GoodwillUSD | 32,300,000Source | 32,300,000Source | 33,700,000Source | 28,000,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,557,100,000Source | 1,697,200,000Source | 1,207,700,000Source | 961,200,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 350,200,000Source | 279,300,000Source | 278,900,000Source | 220,400,000Source |
| Inventory, NetUSD | 183,100,000Source | 157,900,000Source | 111,800,000Source | 102,000,000Source |
| Assets, CurrentUSD | 3,702,500,000Source | 3,873,900,000Source | 3,551,000,000Source | 3,380,300,000Source |
| Other Assets, NoncurrentUSD | 196,900,000Source | 222,100,000Source | 151,800,000Source | 114,300,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 783,800,000Source | 920,000,000Source | 1,182,200,000Source | 1,247,800,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 800,000Source | 800,000Source | 700,000Source | 700,000Source |
| Retained Earnings (Accumulated Deficit)USD | 8,556,900,000Source | 7,222,200,000Source | 6,027,100,000Source | 5,042,300,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 900,000Source | -3,400,000Source | -12,800,000Source | -55,500,000Source |
| Stockholders' Equity Attributable to ParentUSD | 7,096,200,000Source | 6,444,000,000Source | 5,984,800,000Source | 4,796,700,000Source |
| Additional Paid in Capital, Common StockUSD | 2,798,000,000Source | 2,698,900,000Source | 2,549,000,000Source | 2,388,400,000Source |
| Liabilities and EquityUSD | 7,880,000,000Source | 7,364,000,000Source | 7,167,000,000Source | 6,044,500,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 560,600,000Source | 738,100,000Source | 804,400,000Source | 343,200,000Source |
| Accounts Payable, CurrentUSD | 7,100,000Source | 6,000,000Source | 5,600,000Source | 4,100,000Source |
| Other Liabilities, NoncurrentUSD | 223,200,000Source | 181,900,000Source | 77,800,000Source | 104,600,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 480,900,000Source | 338,500,000Source | 292,400,000Source | 225,800,000Source |
| Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after TaxUSD | -5,600,000Source | -11,000,000Source | -15,900,000Source | -18,800,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 85,600,000Source | 72,500,000Source | 53,200,000Source | 51,300,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 147,700,000Source | 144,000,000Source | 39,100,000Source | 106,800,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 70,900,000Source | 400,000Source | 58,500,000Source | 21,700,000Source |
| Increase (Decrease) in InventoriesUSD | 52,600,000Source | 46,900,000Source | 13,600,000Source | 13,400,000Source |
| Deferred Income Tax Expense (Benefit)USD | 97,700,000Source | -64,100,000Source | -64,400,000Source | -50,800,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 1,561,200,000Source | 1,327,100,000Source | 978,000,000Source | 802,500,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 0Source | 0Source | 89,200,000Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -551,300,000Source | 417,200,000Source | -719,600,000Source | -811,500,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 520,500,000Source | 246,500,000Source | 230,400,000Source | 138,800,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 16,600,000Source | 12,200,000Source | 13,800,000Source | 11,400,000Source |
| Payments for Repurchase of Common StockUSD | 1,000,000,000Source | 1,000,000,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -1,150,000,000Source | -1,254,800,000Source | -11,900,000Source | 75,400,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -140,100,000Source | 489,500,000Source | 246,500,000Source | 66,400,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,557,100,000Source | 1,697,200,000Source | 1,207,700,000Source | 961,200,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 13,500,000Source | 40,200,000Source | 56,000,000Source | 29,100,000Source |
| Income Taxes Paid, NetUSD | 313,300,000Source | 400,600,000Source | 332,500,000Source | 275,700,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 147,700,000Source | 144,000,000Source | 39,100,000Source | 106,800,000Source |
| Amortization of Intangible AssetsUSD | 900,000Source | 900,000Source | 300,000Source | 100,000Source |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to SettlementUSD | 600,000Source | 0Source | 1,800,000Source | — |
| DepreciationUSD | 84,700,000Source | 71,600,000Source | 52,900,000Source | 51,200,000Source |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | — | 0Source | 0Source | 1,700,000Source |
| GoodwillUSD | 32,300,000Source | 32,300,000Source | 33,700,000Source | 28,000,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | 379,200,000Source | 343,900,000Source | 289,500,000Source | 223,300,000Source |
| InterestExpenseNonoperatingUSD | 19,500,000Source | 42,900,000Source | — | — |
| Investment Income, InterestUSD | 192,000,000Source | 199,100,000Source | 162,700,000Source | 45,200,000Source |
| Net Income (Loss) Attributable to ParentUSD | 1,334,700,000Source | 1,195,100,000Source | 984,800,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | 727,300,000Source |
| Nonoperating Income (Expense)USD | 221,400,000Source | 162,000,000Source | 89,400,000Source | -29,100,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 4,800,000Source |
| Other Nonoperating Income (Expense)USD | 48,900,000Source | 5,800,000Source | -14,000,000Source | -40,200,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 1,583,900,000Source | 1,537,000,000Source | 2,137,300,000Source | 1,021,500,000Source |
| Proceeds from Stock Options ExercisedUSD | 173,900,000Source | 152,500,000Source | 98,000,000Source | 88,400,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 3,182,700,000Source | 2,877,400,000Source | 2,327,500,000Source | 1,936,300,000Source |
| Cost of RevenueUSD | 384,400,000Source | 309,700,000Source | 257,500,000Source | 151,600,000Source |
| Selling, General and Administrative ExpenseUSD | 755,800,000Source | 709,700,000Source | 477,100,000Source | — |
| Operating Income (Loss)USD | 1,492,500,000Source | 1,377,000,000Source | 1,184,900,000Source | 979,700,000Source |
| Other Nonoperating Income (Expense)USD | 48,900,000Source | 5,800,000Source | -14,000,000Source | -40,200,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 1,713,900,000Source | 1,539,000,000Source | 1,274,300,000Source | 950,600,000Source |
| Income Tax Expense (Benefit)USD | 379,200,000Source | 343,900,000Source | 289,500,000Source | 223,300,000Source |
| Net Income (Loss) Attributable to ParentUSD | 1,334,700,000Source | 1,195,100,000Source | 984,800,000Source | — |
| Earnings Per Share, BasicUSD per share | 30.13Source | 26.44Source | 21.04Source | 15.98Source |
| Earnings Per Share, DilutedUSD per share | 27.86Source | 24.64Source | 19.81Source | 15Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 44,300,000Source | 45,200,000Source | 46,800,000Source | 45,500,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 47,900,000Source | 48,500,000Source | 49,700,000Source | 48,500,000Source |
| Interest Expense (non-operating)USD | 19,500,000Source | 42,900,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 900,000Source | 900,000Source | 300,000Source | 100,000Source |
| Costs and ExpensesUSD | 1,690,200,000Source | 1,500,400,000Source | 1,142,600,000Source | 956,600,000Source |
| Current Income Tax Expense (Benefit)USD | 281,500,000Source | 408,000,000Source | 353,900,000Source | 274,100,000Source |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to SettlementUSD | 600,000Source | 0Source | 1,800,000Source | — |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | — | 0Source | 0Source | 1,700,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Gross ProfitUSD | 2,798,300,000Source | 2,567,700,000Source | 2,070,000,000Source | 1,784,700,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 1,708,400,000Source | — | — | — |
| Interest ExpenseUSD | — | — | 59,300,000Source | 32,400,000Source |
| Investment Income, InterestUSD | 192,000,000Source | 199,100,000Source | 162,700,000Source | 45,200,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | 727,300,000Source |
| Nonoperating Income (Expense)USD | 221,400,000Source | 162,000,000Source | 89,400,000Source | -29,100,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 4,800,000Source |
| Research and Development ExpenseUSD | 550,000,000Source | 481,000,000Source | 408,000,000Source | 322,900,000Source |
Filing attachments
tm2624887d1_ex99-1.htm · 8-K · 2026-09-08
EX-99.1 2 tm2624887d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 For Immediate Release United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., September 8, 2026: United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the company will utilize the remainder of its previously announced $2 billion share repurchase authorization. To co…
Read attachment ↗uthrq22026-ex991.htm · 8-K · 2026-08-05
EX-99.1 2 uthrq22026-ex991.htm EX-99.1 Document Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Second Quarter 2026 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., August 5, 2026: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2026. Total revenues in the second quarter of 2026 decreased by two percent year-over-year to $783.3 million, compa…
Read attachment ↗tm2620809d1_ex99-1.htm · 8-K · 2026-07-23
EX-99.1 2 tm2620809d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors SILVER SPRING, Md. and DURHAM, N.C., July 23, 2026 — United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors appointed Victor Dzau, M.D., to its Board on July 22, 2026. Dr. Dzau recently completed a 12-year tenure as President of the National Academy o…
Read attachment ↗uthrq12026-ex991.htm · 8-K · 2026-05-06
EX-99.1 2 uthrq12026-ex991.htm EX-99.1 Document Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports First Quarter 2026 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 6, 2026: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2026. Total revenues in the first quarter of 2026 decreased by two percent year-over-year to $781.5 million, compared …
Read attachment ↗tm2610558d1_ex99-1.htm · 8-K · 2026-03-30
EX-99.1 2 tm2610558d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2 Nebulized Tyvaso® (treprostinil) Inhalation Solution demonstrated superiority over placebo for the change in absolute forced vital capacity by 130.1 mL and reduced the risk of clinical worsening in patients with idiopathic pulmonary fi…
Read attachment ↗tm268321d1_ex99-1.htm · 8-K · 2026-03-09
EX-99.1 2 tm268321d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 For Immediate Release United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program Agreements for aggregate $1.5 billion Accelerated Share Repurchase (ASR) already executed, with an additional $500 million authorized within the next year SILVER SPRING, M.D. and RESEARCH TRIANGLE PARK, N.C., March 9, 2026: United Therapeutics Corporation (Nasda…
Read attachment ↗